Abstract
Background Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare, progressively debilitating, and fatal disease caused by deposition of aggregated TTR amyloid in multiple organs and tissues. Highly variable disease penetrance has made it difficult to predict disease onset and progression. Clinically validated and non-invasive plasma biomarkers may facilitate earlier diagnosis, treatment initiation, and aid monitoring of disease progression and improvement of symptoms.
Methods Plasma levels of >1000 proteins were measured from consenting patients in the Phase 3 APOLLO study who received either placebo or patisiran and in a cohort of healthy individuals. A linear mixed model determined the impact of patisiran treatment on the time profile of each protein at 0, 9, and 18 months. The most significant protein, neurofilament light chain (NfL), was further assessed using an orthogonal quantitative approach.
Findings A significant change in the levels of 66 proteins was observed following patisiran treatment relative to placebo, with change in NfL, a marker of neuronal damage, the most significant (p<10−20). Analysis of the changes in the levels of these 66 proteins demonstrated that the proteome of patisiran-treated patients trended toward healthy individuals at 18 months. Plasma NfL levels in healthy controls were 4-fold lower than in patients with hATTR amyloidosis with polyneuropathy (16·3 [SD 12·0] pg/mL vs 69·4 [SD 42·1] pg/mL, p<10−16). Levels of NfL at 18 months increased in placebo-treated patients (99·5 [SD 60·1] pg/mL) and decreased in patisiran-treated patients (48·8 [SD 29·9] pg/mL). Moreover, at 18 months, improvement in mNIS+7 compared to baseline in patisiran-treated patients significantly correlated with a reduction in NfL levels (R=0·43, p<10−7).
Interpretation NfL may serve as a biomarker of nerve damage and polyneuropathy in hATTR amyloidosis, as illustrated by the observed correlation with patisiran treatment and improvement in mNIS+7. Measurement of NfL levels may potentially enable earlier diagnosis of polyneuropathy in patients with hATTR amyloidosis and facilitate monitoring of disease progression/regression.
Funding Alnylam Pharmaceuticals.
Competing Interest Statement
Simina Ticau, Gautham V Sridharan, Shira Tsour, William L Cantley, Amy Chan, Jason A Gilbert, David Erbe, Kevin Fitzgerald, Akshay Vaishnaw, and Paul Nioi are all employed by Alnylam. Michael Polydefkis has participated in clinical trials sponsored by Alnylam, Ionis and Pfizer and has received consulting fees from Alnylam, Ionis and Pfizer. David Adams has participated in clinical trials sponsored by Alnylam, Ionis and received consulting fees advisory from Alnylam and Pfizer. Mary M Reilly has participated in a clinical trial sponsored by Ionis and has received consulting fees from Alnylam, Ionis and AKCEA.
Clinical Trial
NCT01960348
Funding Statement
This study was sponsored by Alnylam Pharmaceuticals.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable
